Alex Biese

During Colorectal Cancer Awareness Month, Dr. Shyam Thakkar discussed rates of this disease in young adults, the role of AI and disparities in care.

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory agencies.

The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.

In metastatic urothelial carcinoma, Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing benefit in later lines.

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky.

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will be presented this month.

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.

CURE spoke with Kelly Grosklags of Conversations With Kelly at the Miami Breast Cancer Conference.

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found to be beneficial.

Antihistamines are associated with improvement for patients with metastatic urothelial carcinoma receiving Tecentriq.

JAK inhibitor treatment is associated with a reduction in risk of thromboembolic events for patients with myeloproliferative neoplasms.

Treatment with pimitespib was associated with stable disease in two-thirds of patients with advanced gastrointestinal stromal tumors.

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes.

The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric and gastroesophageal junction cancers.

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in patients with BRCA1/2 mutations.

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy.

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.

On the heels of two FDA approvals in lung cancer treatments, what innovations are next?

The CEO of Triage Cancer discussed the “best-kept secret” of the health care system in an interview with CURE.

The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a risk of new onset psoriasis.

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted in positive responses.

The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant prostate cancer.

For female patients with glioma, pregnancy after receiving a diagnosis of glioma is associated with worse progression-free survival times.

An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.

Dr. Yuan Yuan breaks down studies for patients with breast cancer, such as the phase 3 CompassHER2 RD Trial.